1. 1308OActivity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). (23rd October 2018) Authors: Yao, J C; Strosberg, J; Fazio, N; Pavel, M E; Ruszniewski, P; Bergsland, E; Li, D; Tafuto, S; Raj, N; Campana, D; Hijioka, S; Raderer, M; Guimbaud, R; Gajate, P; Pusceddu, S; Reising, A; Degtyarev, E; Mookerjee, B; Aimone, P; Singh, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 477PFolfiri-aflibercept vs folfiri-bevacizumab as second line treatment of RAS mutated metastatic colorectal cancer in real practice. (23rd October 2018) Authors: Ottaiano, A; Capozzi, M; De Divitiis, C; Cassata, A; De Stefano, A; Tafuto, S; Avallone, A; Nasti, G Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P-263Survival analysis of a multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC). (20th June 2018) Authors: Avallone, A; Nasti, G; Rosati, G; Carlomagno, C; Romano, C; Bilancia, D; De Stefano, A; Silvestro, L; Ottaiano, A; Cassata, A; Bianco, F; Izzo, F; Delrio, P; De Gennaro, E; Casaretti, R; Tafuto, S; Albino, V; Pace, U; Lastoria, S; Gallo, C Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗